DrugPatentWatch Database Preview
Drugs in Development Information for KAE609
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug KAE609?
KAE609 is an investigational drug.
There have been 6 clinical trials for KAE609.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2013.
The most common disease conditions in clinical trials are Malaria, Malaria, Falciparum, and Malaria, Vivax. The leading clinical trial sponsors are Novartis Pharmaceuticals, This trial is supported in part by Wellcome Trust via Grant # Grant Number 217692/Z/19/Z, and Medicine for Malaria Venture.
There are three US patents protecting this investigational drug and sixty-three international patents.
Summary for KAE609
| US Patents | 3 |
| International Patents | 63 |
| US Patent Applications | 3 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-07-01) |
| Vendors | 22 |
Recent Clinical Trials for KAE609
| Title | Sponsor | Phase |
|---|---|---|
| Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects | This trial is supported in part by Wellcome Trust via Grant # Grant Number 217692/Z/19/Z | Phase 1 |
| Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects | Novartis Pharmaceuticals | Phase 1 |
| Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria. | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for KAE609
Top disease conditions for KAE609
Top clinical trial sponsors for KAE609
US Patents for KAE609
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| KAE609 | Start Trial | Organic compounds | Novartis AG (Basel, CH) | Start Trial |
| KAE609 | Start Trial | Organic compounds | Novartis AG (Basel, CH) | Start Trial |
| KAE609 | Start Trial | Chemical process for preparing spiroindolones and intermediates thereof | Novartis AG (Basel, CH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for KAE609
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| KAE609 | Argentina | 071222 | 2028-04-29 | Start Trial |
| KAE609 | Australia | 2009242279 | 2028-04-29 | Start Trial |
| KAE609 | Brazil | PI0911577 | 2028-04-29 | Start Trial |
| KAE609 | Canada | 2719365 | 2028-04-29 | Start Trial |
| KAE609 | Chile | 2009001007 | 2028-04-29 | Start Trial |
| KAE609 | China | 102015711 | 2028-04-29 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
